HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S 0139 (97-139)

structure given in first source; ET(A) receptor antagonist

Also Known As:

97-139; 27-O-3-(2-(3-carboxyacryloylamino)-5-hydroxyphenyl)acryloyloxymyricerone, sodium salt; S-0139

Networked: 12 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Triterpenes: 2493
      - Pentacyclic Triterpenes: 108
        Oleanolic Acid: 547
        S 0139: 12
      - Sapogenins: 26
        Oleanolic Acid: 547
        S 0139: 12
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Cinnamates: 48
      - Caffeic Acids: 15
        S 0139: 12

Experts

1.	Alpermann, T: 1 article (07/2014)
2.	Bacher, U: 1 article (07/2014)
3.	Eder, C: 1 article (07/2014)
4.	Haferlach, C: 1 article (07/2014)
5.	Haferlach, T: 1 article (07/2014)
6.	Kern, W: 1 article (07/2014)
7.	Krauth, M-T: 1 article (07/2014)
8.	Nadarajah, N: 1 article (07/2014)
9.	Schnittger, S: 1 article (07/2014)
10.	Hassn, A: 1 article (08/2010)

Related Diseases

1.	Infarction (Infarctions) 10/01/2008 - "The combination therapy of S-0139 and rtPA significantly (P<0.01) reduced infarct volume (24.8+/-0.9% versus 33.8+/-1.5% in control) and hemorrhagic area (7.1+/-6.1 microm(2) versus 36.5+/-19.2 microm(2) in control) and improved functional recovery compared with control saline-treated animals. " 09/01/2001 - "When the infusion of S-0139 was begun after 10 minutes and 1 hour of reperfusion, the brain edema formation and infarct size were significantly attenuated. " 09/01/2001 - "We examined the brain tissue ET-1 content and evaluated the time and dose response of the therapeutic effects of the specific ET type A receptor (ET(A)) antagonist, S-0139, on brain edema formation, development of infarction, and disruption of BBB after 1 hour of middle cerebral artery occlusion (MCAO) in rats. "
2.	Brain Ischemia (Cerebral Ischemia) 09/01/2001 - "Furthermore, posttreatment with S-0139 significantly attenuated the increased Evans blue dye-quantified albumin extravasation and improved the mortality of animals after cerebral ischemia/reperfusion. "
3.	Brain Injuries (Brain Injury) 09/01/2001 - "Our data demonstrate that infusion with S-0139, an ET(A) antagonist, results in significant reduction of brain injury and plasma extravasation after transient MCAO. "
4.	Thrombosis (Thrombus) 10/01/2008 - "These data suggest that S-0139 provides the neuroprotection by suppressing ischemia- and rtPA-triggered molecules that evoke thrombosis and BBB disruption." 10/01/2008 - "Using a model of embolic stroke, the present study tested the hypothesis that blockage of endothelin-1 with S-0139, a specific endothelin type A receptor (ET(A)) antagonist, enhances the neuroprotective effect of recombinant tissue plasminogen activator (rtPA) by suppressing molecules that mediate thrombosis and blood brain barrier (BBB) disruption induced by ischemia and rtPA. "
5.	Ischemia 10/01/2008 - "These data suggest that S-0139 provides the neuroprotection by suppressing ischemia- and rtPA-triggered molecules that evoke thrombosis and BBB disruption." 10/01/2008 - "Using a model of embolic stroke, the present study tested the hypothesis that blockage of endothelin-1 with S-0139, a specific endothelin type A receptor (ET(A)) antagonist, enhances the neuroprotective effect of recombinant tissue plasminogen activator (rtPA) by suppressing molecules that mediate thrombosis and blood brain barrier (BBB) disruption induced by ischemia and rtPA. "

Related Drugs and Biologics

1.	Evans Blue (Blue, Evans)
2.	Coloring Agents (Dyes)
3.	Albumins
4.	Endothelins (Endothelin)
5.	Endothelin-1 (Endothelin 1)
6.	Neuroprotective Agents
7.	Tissue Plasminogen Activator (Alteplase)
8.	Endothelin Receptor Antagonists
9.	Therapeutic Uses
10.	Endothelin A Receptor

Related Therapies and Procedures

1.	Therapeutics